Alok-Srivastava-elected-to-BOD-2024

Alok Srivastava elected to WFH board of directors as Medical Member

The World Federation of Hemophilia (WFH) is very pleased to announce that Alok Srivastava, MD, was elected to the WFH Board of Directors as a Medical Member at the Annual Meeting of the General Assembly at the WFH 2024 World Congress in Madrid, Spain, for a four-year term.

Also available in: Français Español

Alok Srivastava, MD is a hematologist based in Vellore, India with over three decades of experience. He is currently Senior Professor, Department of Hematology, Christian Medical College, Vellore, India, and President of the Indian Association for Hemophilia and Allied Disorders. Srivastava has a medical degree from the University of Madras, India, with a subspecialty in hematology.

Srivastava has worked on medical training programs through the WFH International Hemophilia Training Centre (IHTC) Fellowship Program, supported the development of the WFH Annual Global Survey (AGS), and has led the development of all three editions of the WFH Guidelines for the Management of Hemophilia, including the 3rd edition. He has also been part of the WFH Coagulation Products Safety Supply and Accessibility Committee, as well as the WFH Global Forum and the WFH Gene Therapy Round Tables.

Alok Srivastava’s invaluable experience will be a great asset to the WFH as a Medical Member. Please join us in welcoming him to the WFH Board of Directors.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.